NCT03436849View on ClinicalTrials.gov

A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ESN364 in Healthy Japanese Male and Pre- and Post-menopausal Female Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

February 22, 2018

Primary Completion Date

May 23, 2018

Study Completion Date

May 23, 2018

Conditions
Healthy Subjects
Interventions
DRUG

ESN364

ESN364 will be administered orally.

DRUG

Placebo

Placebo will be administered orally.

Trial Locations (1)

Unknown

Site JP00001, Fukuoka

Sponsors
All Listed Sponsors
lead

Astellas Pharma Inc

INDUSTRY

NCT03436849 - A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ESN364 in Healthy Japanese Male and Pre- and Post-menopausal Female Subjects | Biotech Hunter | Biotech Hunter